1. Home
  2. GNLX vs LUNG Comparison

GNLX vs LUNG Comparison

Compare GNLX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

N/A

Current Price

$2.52

Market Cap

110.4M

Sector

Health Care

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.91

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNLX
LUNG
Founded
2001
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.4M
97.1M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
GNLX
LUNG
Price
$2.52
$1.91
Analyst Decision
Strong Buy
Buy
Analyst Count
6
5
Target Price
★ $18.83
$3.40
AVG Volume (30 Days)
211.2K
★ 255.6K
Earning Date
11-04-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 9.47
7.64
EPS
★ N/A
N/A
Revenue
$8,000.00
★ $90,497,000.00
Revenue This Year
N/A
$0.06
Revenue Next Year
N/A
$8.58
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$2.29
$1.13
52 Week High
$8.54
$2.89

Technical Indicators

Market Signals
Indicator
GNLX
LUNG
Relative Strength Index (RSI) 49.81 44.84
Support Level $2.51 $1.20
Resistance Level $2.93 $2.12
Average True Range (ATR) 0.12 0.10
MACD 0.01 -0.01
Stochastic Oscillator 72.66 36.65

Price Performance

Historical Comparison
GNLX
LUNG

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: